Kymera Therapeutics Inc. has published the characterization of KT-253, a novel compound designed to degrade the murine double minute 2 (MDM2) protein, offering a promising approach for cancers retaining wild-type p53.
Wall Street nicked shares of Karyopharm Therapeutics Inc. after the firm offered top-line results from the 263-subject phase III study with Xpovio (selinexor) in advanced or recurrent endometrial cancer (EC). Shares (NASDAQ:KPTI) closed at $8.19, down $2.05, or 20%, having dropped as low as $7.66.
